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Heterologous prime-boost regimens are eﬀective strategies to promote long-term memory and strong cellular Th1 responses
to Mycobacterium tuberculosis, when BCG is used in the priming step. Subcutaneous or intranasal boosting of BCG-vaccinated
newborn mice with native heparin-binding haemagglutinin (nHBHA) signiﬁcantly enhances protection against M. tuberculosis.
However, nHBHA is characterized by a complex methylation pattern in its C-terminal domain, which is important for protective
immunogenicity in primary vaccination. In this study we addressed the question whether boosting with recombinant, non-
methylated HBHA (rHBHA) produced in Escherichia coli may enhance protection of BCG-primed newborn mice. We found
that while subcutaneous rHBHA boosting enhanced protection of BCG-primed mice against intranasal M. tuberculosis infection
both in spleen and lungs, enhanced protection against aerosol infection was only seen in the spleen (0.72 logs; P<0.05) but not
in the lungs. Thus, in BCG-primed mice the methylation of the C-terminal domain of HBHA is dispensable for the induction of
enhanced protection in the lungs against intranasal but not aerosol infection, whereas it enhances protection in the spleen in both
challenge models. This report thus provides evidence that rHBHA may be considered as a booster vaccine against disseminated
tuberculosis.
1.Introduction
Tuberculosis (TB)remains one of the main causes ofmortal-
ity in the world [1, 2]. Mycobacterium bovisBacille Calmette-
Gu´ erin (BCG) [3], a live, attenuated mycobacterial strain is
still the only vaccine available against TB. While it has clear
beneﬁcial eﬀects against pulmonary and disseminated TB in
childrenforalimitednumberofyears,itprovidesinsuﬃcient
protection against pulmonary tuberculosis in adults, with
highly variable protective eﬃcacy [1, 4]. Therefore, more
eﬀectivevaccines toincrease orboost BCG-induced immune
protection against TB are urgently needed. Recent advances
have shown that non-living vaccines based on secreted pro-
teins and prime-boost strategies [5, 6]c a ne ﬀectively protect
against subsequent Mycobacterium tuberculosis infection in
animal models and increase immune responses in humans
[7–11].
The most desirable immunological consequence of the
vaccinationwithBCGistheprimingofaTh1-orientedCD4+
T cell response that maximizes, through the release of IFN-
γ, the antimicrobial properties of macrophages [12–14]. In
this sense, it has been demonstrated that the mycobacterial
adhesin heparin-binding haemagglutinin (HBHA) [15, 16]
is a promising antigen against TB [17, 18]. HBHA is a
methylated protein, and the methylation pattern in its
C-terminal domain is important for the production of
HBHA-speciﬁcIFN-γ byperipheralbloodmononuclearcells
(PBMCs) from M. tuberculosis-infected healthy individuals
[17]. In mouse models, methylated HBHA, but not recom-
binant, non-methylated HBHA (rHBHA), co-administered2 Clinical and Developmental Immunology
with the adjuvant dimethyl dioctadecylammonium bromide
monophosphoryl lipid A (DDA+MPL) induced protection
against intravenous (i.v.) or aerosol challenge with M.
tuberculosis at levels similar to those induced by BCG
[17–19], indicating the importance of the methylated C-
terminal domain of HBHA for protection. However, the N-
terminal domain is predicted to contain helix-coiled coil
motifs, which are usually rich in T and B cell epitopes
[20, 21]. Consistent with this, we have previously reported
thatrHBHAwithoutadjuvant,administered toadultBALB/c
mice by the intranasal (i.n.) or subcutaneous (s.c.) route,
induces signiﬁcant humoral and T cell immune responses
[22], although protective immunity was not observed. On
the other hand, we have also shown that native HBHA
administered by the s.c. or i.n. route without adjuvant sig-
niﬁcantly enhances BCG-primed immunoprotection against
M. tuberculosis infection [23]. In this study, we investigated
whether; in a similar heterologous prime-boost regimen
[23], rHBHA boosting confers enhanced protection against
aerosol or i.n. M. tuberculosis infection in BCG-primed
mice. We found that the methylation of the C-terminal
domain of HBHA can be dispensable for the boosting eﬀect
of BCG-induced protective immunity in the lungs against
i.n., but not aerosol M. tuberculosis infection, whereas it
enhances protection in the spleen in both infection models.
We therefore conclude that rHBHA may be considered as
a booster vaccine to improve the eﬃcacy of BCG for the
prevention of disseminated TB to non-pulmonary locations.
2.MaterialandMethods
2.1. Animals. Pathogen-free newborn (three to four days
old) BALB/c mice were obtained from Harlan, Co, France
and were maintained in a speciﬁc pathogen-free envi-
ronment at the Institut Pasteur of Lille throughout the
entire experiment. All animal experiments were performed
according to the protocols approved by the Institutional
Animal Care and Use Committee and mainly under barrier
conditions in a level II and III biosafety animal facility.
2.2. Microorganisms. The BCG Pasteur strain (isolate
1173P2, World Health Organization, Stockholm, Sweden)
was grown in dispersed cultures in Sauton medium for
14 days as previously described [15]. The BCG suspension
was then stored at –80◦Cu n t i lf u r t h e ru s e .M. tuberculosis
H37Rv used to challenge mice was grown at 37◦C in Middle-
brook 7H9 medium (DIFCO), supplemented with albumin-
dextrose-catalase enrichment and Tween 80, collected at the
end of the stationary phase and stored in Middlebrook 7H9
medium supplemented with 20% (v/v) glycerol at –80◦C
until they were used.
2.3. Immunizations. Recombinant HBHA was puriﬁed from
Escherichia coli BL21(DE3)(pET-HBHA) [16]b yu s i n g
heparin-sepharose chromatography, followed by reverse
phase high-pressure liquid chromatography, as previously
described [15, 24]. Groups of 3-4-day-old neonate BALB/c
mice were immunized s.c. [23]w i t h5× 105 colony-forming
units (CFU) BCG in 50μL sterile phosphate-buﬀered saline
(PBS) or mock-immunized with 50μLo fs t e r i l eP B S .A t
intervals of one month, for a total of three months, each
groupofmicewasboosteds.c.with5μgrHBHA,dissolvedin
150μLofPBSorascontrolreceivedonlyPBS[23].Micewere
rested one month before M. tuberculosis challenge infection.
2.4. M. tuberculosis Challenge. For the i.n. challenge experi-
ments, mice were ﬁrst anesthetized with an intra-peritoneal
(i.p.) injection of sodium pentobarbital (1/10 of the weight
mouse) and then infected i.n. with 5 × 105 CFUs of
M. tuberculosis in 20μL of PBS. Alternatively, mice were
aerosol-challenged by using a homemade nebulizer. 3mL
of a suspension containing 2 × 107 CFUs was aerosolized
to deliver an inhaled dose of 100–150 CFUs per mouse.
Numbers of live bacteria in organs were measured eight
weeks after infection by plating serial dilutions of whole
organ homogenates on Middlebrook 7H11 solid medium
supplemented with 2mg/mL of THF. Petri dishes were kept
in sealed plastic bags at 37◦C for 3-4 weeks. Colonies were
counted and total CFU calculated.
2.5. Cytokine Analyses. For cytokine measurements single
cell suspensions of spleen or lung cells were prepared as
describedelsewhere[22].Brieﬂy,spleentissuesweresmashed
in a Falcon sieve using the top end of a 1mL syringe
piston. The excised lung tissue was minced and incubated
for 1h at 37◦C in 500μL of PBS containing 2% fetal bovine
serum (FBS) (Buﬀer I), 125U/mL collagenase I (Sigma-
Aldrich), and 60U/mL DNase I (Sigma-Aldrich). Single cell
suspensions were prepared by passing the tissue through a
30-mm stainless steel mesh, washed, resuspended in BuﬀerI,
applied carefully onto a gradient of percoll (Sigma-Aldrich),
and centrifuged at 2200rpm for 30min at 20◦C. Live cells
at the interface were collected and used for in vitro culture.
1 × 106 viable cells were cultured in medium consisting of
RPMI 1640 (GIBCO BRL) supplemented with 10% heat-
inactivated FBS, 2mM L-glutamine, 10mM HEPES, 100U
of penicillin G per mL, 100μg of streptomycin per mL, and
0.05mM 2-mercaptoethanol. Cells were incubated at 37◦C
in an atmosphere of 5% CO2 for 72h in 96-well ELISA
plates in the presence or absence of ConA (2.5μg/mL) or
rHBHA (2.5μg/mL). The culture supernatants were then
collected and stored at −20◦C until analysis. The amounts
of IL-6, IFN-γ, IL-12p70, and IL-10 in the supernatants were
measured by using a speciﬁc sandwich ELISA (OptEIA; BD
Biosciences-Pharmingen) according to the manufacturer’s
instructions. Assay sensitivities were 2.5pg/mL for IFN-γ
and 3pg/mL for IL-6, IL12p70, and IL10. The data are
expressed as the mean ± SEM for each mouse group.
2.6. Statistical Analysis. Diﬀerences between the diﬀerent
groups (three) were assessed by one-way analysis of variance
(ANOVA) and by its nonparametric equivalent Kruskal-
Wallis testofthe log10 CFUfollowed by Tukeyand/orDunn’s
post-test, respectively. A value of P<0.05 was considered
statistically signiﬁcant. Analysis was performed using PrismClinical and Developmental Immunology 3
5.0 software (Graph Pad Software, Inc., Sand Diego, Calif,
USA).
3.Results
3.1. The Methylation Pattern in the C-Terminal Domain of
HBHA Is Dispensable to Boost Protection of BCG-Vaccinated
Newborn Mice against M. tuberculosis i.n. Challenge. The
natural methylation pattern in the C-terminal domain of
HBHA is important for T cell antigenicity and protective
immunity [17]. No protective immunity was induced when
rHBHA was co-administered with the adjuvant DDA+MPL
to adult BALB/c or C57BL/6 mice challenged i.v. or through
the aerosol route with M. tuberculosis [17, 18]. However,
it has been shown that heterologous prime-boost regimens
are eﬃcient to boost BCG-induced immunity against M.
tuberculosis [5, 9]. We have recently reported that boosting
(i.n. or s.c.) with nHBHA in the absence of adjuvant
was an eﬃcient way to signiﬁcantly enhance BCG-induced
immunoprotection against M. tuberculosis infection [23].
Taking into account that rHBHA is easily puriﬁed from
recombinant E. coli, we investigated whether this form of
HBHA may also boost BCG-induced protective immunity.
Therefore, newborn mice were vaccinated with BCG and
then boosted with rHBHA by the s.c. route. One month
after the last immunization, the mice were infected with M.
tuberculosis and sacriﬁced 8 weeks after challenge to count
the CFUs in spleen and lungs, as a measure of protec-
tion. BCG-primed/rHBHA-boosted mice had a signiﬁcantly
reduced bacterial load in the spleen (by 1.32 logs, P<0.05)
in comparison with PBS control mice (3.72 ± 0.12 versus
5.04 ± 0.29) (Table 1), which was signiﬁcantly lower than
in BCG-vaccinated, non-boosted animals (by 0.89 logs, P<
0.05; 3.72 ± 0.12 versus 4.15 ± 0.55) (Table 1). Furthermore,
in the lungs BCG-vaccinated/rHBHA-boosted mice had also
signiﬁcantly reduced bacterial loads compared to the PBS
controls (by 2.26 logs, P<0.05; 3.98 ± 0.11 versus 6.24 ±
0.2 5 )a n dc o m p a r e dt oB C G - v a c c i n a t e dn o n - b o o s t e dm i c e
(by 1.26 logs, P<0.05; 3.98 ± 0.11 versus 5.24 ± 0.40)
(Table 1). These data indicate that the methylation pattern
in the C-terminal domain of HBHA is dispensable for the
booster eﬀect of BCG-induced protective immunity after i.n.
M. tuberculosis infection.
3.2. The Methylation Pattern in the C-Terminal Domain
of HBHA Is Important to Boost Lung Protection of BCG-
Vaccinated Newborn Mice against M. tuberculosis Aerosol
Challenge. Next, we evaluated the rHBHA boosting eﬀect of
the BCG-induced protective immunity against M. tuberculo-
sis aerosol infection. BCG-vaccinated newborn mice boosted
with rHBHA were challenged by aerosol with a low dose
of M. tuberculosis (∼100–150 CFUs). Eight weeks post-
challenge, BCG-vaccinated/rHBHA-boosted mice showed a
signiﬁcant reduction of bacteria in the spleen (by 1.35 logs,
P<0.05) in comparison with PBS control mice (3.15 ±
0.71 versus 4.50 ± 0.46) (Table 1), as well as in comparison
with BCG-vaccinated, non-boosted mice (by 0.72 logs, P<
0.05; 3.15 ± 0.71 versus 3.87 ± 0.34) (Table 1). In contrast,
in the lungs, both BCG-vaccinated non-boosted and BCG-
vaccinated/rHBHA-boosted mice showed reduced bacterial
load atasimilar magnitudein comparisontothePBScontrol
mice (by 0.59 logs) (Table 1) .T h u s ,i nc o n t r a s tt ot h ei . n .
M. tuberculosis infection, upon aerosol challenge rHBHA
boostingdidnotenhanceBCG-inducedprotectiveimmunity
in the lung, while it boosted protection in the spleen. These
data indicate therefore that natural methylation present
in the C-terminal of nHBHA and absent in rHBHA is
important to enhance BCG-induced protective immunity
in the lungs, but not in the spleen against M. tuberculosis
aerosol-infection.
3.3. rHBHA Boosting of BCG-Induced Protective Immunity
a g a i n s ti . n .C h a l l e n g eC o r r e l a t e sw i t hH i g hI L - 1 2P r o d u c -
tion. We have previously reported that in the absence of
DDA+MPL, nHBHA boosting of the BCG-induced protec-
tiveimmunity against i.n. oraerosol M.tuberculosis infection
correlates with high IL-12 and TGF-β production [23], two
cytokines that are important for the maintenance of the
memory T cell population[25–27],especially when boosting
occurs late after priming. Therefore, we determined whether
the rHBHA-mediated booster eﬀect of the BCG-induced
protective immunity after M. tuberculosis infection (either
i.n./or aerosol) also correlates with these two cytokines
induced after challenge in a long-term prime boost protocol
and in vitro recall with rHBHA.
Splenocytes from i.n. infected mice after in vitro recall
with rHBHA produced signiﬁcant amounts of IL12p70
(3325 ± 403pg/mL) (Figure 1A, gray bar), in comparison
with PBS-immunized mice (850 ± 508pg/mL) (Figure 1A,
white bar) and BCG-vaccinated non-boosted mice (1540 ±
239pg/mL) (Figure 1A, black bar). In contrast, the spleen
cell TGF-β production in BCG-vaccinated/rHBHA-boosted
mice after infection was similar (2174 ± 270pg/mL) to
that of spleen cells from the BCG-vaccinated i.n. infected
mice without boost (2291 ± 203pg/mL) (Figure 1A). BCG-
vaccinated/rHBHA-boosted mice also produced slightly
higher amounts of IFN-γ (505 ± 150pg/mL, P<0.05)
(Figure 1A) after infection, in comparison with those
induced by the BCG-vaccinated non-boosted mice (252 ±
14pg/mL) (Figure 1A) and PBS control mice (236 ± 32)
(Figure 1A). We also determined regulatory (IL-10) and
Th17 typecytokines(IL-6,IL-17)andfoundthat splenocytes
from BCG-vaccinated/rHBHA-boosted i.n. infected mice
induced a signiﬁcant IL-10 production (1640 ± 100pg/mL)
in comparison with infected PBS control mice (76 ±
2 0p g / m L )a n di n f e c t e dB C G - v a c c i n a t e dm i c ew i t h o u tb o o s t
(304 ± 14pg/mL) (Figure 1A). Interestingly, the IL-6 spleen
cell production from BCG-vaccinated/rHBHA-boosted i.n.
infectedmice(427±89pg/mL)wassimilartothatofthenon-
boosted group (419 ± 20pg/mL), but signiﬁcantly higher
thanthatofthePBScontrolmice(96±4pg/mL)(Figure 1A).
Spleen cell IL-17 production signiﬁcantly changed between
the three groups after i.n. infection (Figure 1A).
After aerosol infection, splenocytes from BCG-vaccinat-
ed/rHBHA-boosted mice produced similar amounts of IL-
12p70 (3020 ± 42pg/mL) as those from BCG-vaccinated4 Clinical and Developmental Immunology
Table 1: Diﬀerential recombinant HBHA boosting eﬀect of BCG-induced protective immunity in BALB/c newborn mice against M. tuber-
culosis H37Rv infection as measured by reduced bacterial load in spleen and lungs.
Vaccine Lung CFUsa
Lung protection
Spleen CFUsa
Spleen protection
Versus Versus
Control BCG Control BCG
Control
b 6.24 ±0.25 5.04 ± 0.29
BCG
b 5.24 ± 0.40 1.0∗ 4.15 ± 0.55 0.89∗
BCG-rHBHA
b 3.98 ±0.11 2.26∗ 1.26∗∗ 3.72 ± 0.12 1.32∗ 0.43∗∗
Control
c 4.50 ±0.71 4.50 ± 0.46
BCG
c 3.91 ±0.28 0.59∗ 3.87 ± 0.34 0.63∗
BCG-rHBHA
c 3.91 ±0.47 0.59∗ 3.15 ± 0.71 1.35∗ 0.72∗∗
aData are represented as mean ± standard deviations of the log10-transformed bacterial (CFUs) of M. tuberculosis per organ; bintranasal challenge; caerosol
challenge. Protection is calculated with respect to control of vaccination (BCG) and with respect to PBS-immunized newborn mice (control). The data
reported are ∗signiﬁcant at P<0.05 with respect to control mice and ∗∗signiﬁcant at P<0.05 with respect to BCG control of vaccination with no boost.
One representative of a total of two independent experimentsis shown.
non-boosted mice (3020 ± 313pg/mL) (Figure 1B), but
higher than those from the PBS control mice (2720 ±
170pg/mL) (Figure 1B ) .As i m i l a rp a t t e r nw a so b s e r v e df o r
the spleen cell TGF-β production (BCG: 1540 ± 367pg/mL;
BCG/rHBHA:1755±450pg/mL;controls:970±403pg/mL).
Interestingly, after aerosol infection, spleen cells from BCG-
vaccinated/rHBHA-boosted mice produced also a mod-
est but signiﬁcant amount of IFN-γ (760 ± 312pg/mL)
(Figure 1B, gray bar), higher than spleen cells from BCG-
vaccinated mice without boost (300±68pg/mL) (Figure 1B,
blackbar)andPBScontrolmice(159±10pg/mL)(Figure 1B,
blank bars) (P<0.05). The spleen cell production of IL-10,
IL-17, and IL-6 was not signiﬁcantly diﬀerent between the
diﬀerent groups of aerosol-infected mice (Figure 1B).
Thus it appears that for some cytokinesthe boostereﬀect
of rHBHA upon BCG priming depends on the route of
infection (i.n. for IL-12, IL-10; aerosol and i.n. for IFN-γ).
3.4. Th1-Type Cytokine Induction in the Lungs from BCG-
Vaccinated/rHBHA-Boosted Mice after Infection. To deter-
mine whether the enhanced lung protective eﬀect of BCG-
vaccinated/rHBHA-boosted mice against i.n. infection com-
pared to BCG-vaccinated, non-boosted mice also correlates
with high IL-12 and/or TGF-β production, eight weeks after
challenge (either i.n. or aerosol), the cytokine production
was determined in the supernatant of the lung cell cultures
after in vitro recall with rHBHA.
Lung cell IL-12 production of BCG-vaccinated/rHBHA-
boosted mice infected i.n. was signiﬁcantly higher
(3800 ± 560pg/mL) (Figure 2A) than that of non-
boosted mice (2280 ± 335pg/mL) or PBS control mice
(433 ± 222pg/mL) (Figure 2A). Interestingly, the lung
cells from BCG-vaccinated/rHBHA-boosted mice also
produced higher amounts of TGF-β (2240 ± 290pg/mL)
after i.n. infection, in comparison with non-boosted mice
(1707 ± 122pg/mL) and the controls (489 ± 277). The
lung cell IL-10 production was signiﬁcantly higher in
BCG-vaccinated/rHBHA-boosted mice (1955 ± 275pg/mL)
than in non-boosted (252 ± 42pg/mL) and in control
mice (68 ± 7pg/mL) after i.n. infection (Figure 2A).
Very low levels of IFN-γ were produced by lung cells
in all three groups (Figure 2A). The lung cell IL-6 and
IL-17 production was higher in the BCG-vaccinated
non-boosted mice (451 ± 33pg/mL) than in the BCG-
vaccinated/rHBHA-boosted (271 ± 37) and in the PBS
control mice (133 ± 7pg/mL) after i.n. infection. No
diﬀerence in lung cell IL-17 production between boosted
and non-boosted mice was seen (Figure 2A).
Although the lung cells from BCG-vaccinated/rHBHA-
boosted mice infected by the aerosol route with M. tubercu-
losis produced a similar cytokine pattern (IL-12, IFN-γ,I L - 6 ,
and IL-17) as those from mice infected by i.n. route, there
were no statistically signiﬁcant diﬀerences between rHBHA-
boosted and non-boosted animals (Figure 2B). Together
these results suggest that the rHBHA boosting eﬀect of
BCG-induced protective immunity after i.n. M. tuberculosis
infection correlates essentially with high IL-12 production
(Figure 2A), since, after aerosol infection, lung cells from
BCG-vaccinated/rHBHA-boosted mice produced a lower
magnitude of IL-12 (Figure 2B). Thus, the absence of the
methylation pattern in the C-terminal domain does not
aﬀect the induction of cytokines important for the T cell
memory response but is important for the magnitude,
speciﬁcally of IL-10 and IL-12.
4.Discussion
The natural methylation in the C-terminal domain of
mycobacterial HBHA [15, 16] plays an important role in T
cell antigenicity and protective immunity [17–19]. In this
w o r k ,w er e p o r tt h a tt h em e t h y l a t i o np a t t e r ni nt h eC -
terminal domain of HBHA is dispensable for the booster
eﬀect of the BCG-induced protective immunity against
i.n. M. tuberculosis infection but is important to enhance
protection in lungs after aerosol challenge.
rHBHA, a protein without the C-terminal methylation,
can be easily puriﬁed from recombinant E. coli and is able
to induce strong humoral and cellular immune responses
when is administered without the adjuvant DDA+MPL by
the s.c. or i.n. route to BALB/c mice [22], suggesting that the
α-helical regions in the N-terminal domain can be target of
B and T cell receptors [20, 21]. However, co-administrationClinical and Developmental Immunology 5
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Figure 1:SpleencellcytokineproﬁleofBCG-vaccinated micewithorwithoutrHBHAboostafterM.tuberculosis infection.Eight weeksafter
i.n.(A) oraerosol(B) challenge spleen cells from control mice (white bars),BCG-vaccinated mice (black bars),or BCG-vaccinated/rHBHA-
boosted mice (gray bars) were cultured in the presence of medium only, ConA (2.5μg/mL), or rHBHA (5μg/mL). Levels of cytokines were
measured after 72h culture in the supernatants by using the OptEIA kit (BD Biosciences). Values are expressed in pg/mL and represent
media ± SEM of samples tested in duplicates from each group of mice. The data was considered statistically signiﬁcant when P<0.05 (∗),
P<0.001 (∗∗), and P<0.0001 (∗∗∗).
of rHBHA plus the DDA+MPL was unable to protect adult
mice from i.v. or aerosol infection with M. tuberculosis
[17, 18]. Heterologous prime boost regimens are an eﬃcient
wayto inducelong-term memory cellular immune responses
leading to enhanced protection against M. tuberculosis [5,
9, 23]. We have recently shown that both i.n. and s.c.
boosting with nHBHA in the absence of the strong Th1-
adjuvant (DDA+MPL) were able to signiﬁcantly enhance
protection against an i.n. or aerosol M. tuberculosis challenge
in BCG-primed, newborn mice [23]. Keeping with these
observations,itwas conceivabletothinkthat,underasimilar
prime-boost regimen, rHBHA without methylation in the
C-terminal domain and without adjuvant (DDA+MPL)
could enhance BCG-induced protective immunity against
M. tuberculosis infection. The ﬁndings of this work indicate
that,whilethemethylationpatternintheC-terminaldomain
of HBHA is dispensable for the rHBHA boosting eﬀect
of the BCG-induced protective immunity against i.n. M.
tuberculosis challenge,itisessential toinducelungprotection
after aerosol infection of mice with M. tuberculosis.
Although the most desirable eﬀect of the vaccination
with live BCG is the induction of a strong pro-Th1-type
CD4+ T cell response through the release of IFN-γ [12, 13,
27], several studies have shown that enhanced protection
does not necessarily correlate with the presence of IFN-γ-
producing circulating cells. As mentioned above, heterolo-
gous prime/boost strategies are a very eﬀective strategy to
enhance protection against M. tuberculosis because of the
induction of cytokines (IL-12, IL-17, and TGF-β)[ 25, 26]
that promote the development and maintenance of long-
term memory T cells [28, 29]. In agreement with this, we
recently reported that enhanced BCG-mediated protective
immunity against M. tuberculosis infection correlated pre-
cisely with these cytokines in the systemic and mucosal
compartments. Interestingly, in this work we have found
that BCG-vaccinated/rHBHA-boosted mice were protected
against i.n. M. tuberculosis infection, and this enhanced
protection correlated with high amount of spleen and lung
IL-12 production, as well as lung TGF-β production. In
addition, IL-10 production was detected in spleen and lungs6 Clinical and Developmental Immunology
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Figure 2: Lung cell cytokine proﬁle of BCG-vaccinated mice with or without rHBHA boost after M. tuberculosis infection. Eight weeks after
i.n. (A) or aerosol (B) challenge lung cells from control mice (white bars), BCG-vaccinated mice (black bars), or BCG-vaccinated/rHBHA-
boosted mice (gray bars) were cultured in the presence of medium only, ConA (2.5μg/mL), or rHBHA (5μg/mL). Levels of cytokines were
measuredafter72hculture inthesupernatantsbyusingtheOptEIAkit(BDBiosciences).Valuesareexpressed inpg/mLandrepresent media
± SEM of samples tested in duplicates from each group of mice. Statistically signiﬁcant data: P<0.05 (∗), P<0.001 (∗∗), and P<0.0001
(∗∗∗).
after i.n. infection, suggesting that the lack of methylation
in the C-terminal domain of HBHA could inﬂuence a
more complex interplay between Th1 and regulatory type
cytokines, in agreement with what has been reported else-
where concerningthe eﬀectof IL-10 on the Th1-type cellular
immune response upon vaccination [30, 31]. It is possible
that, in our model, the high IL-10 production after i.n. M.
tuberculosis infection of BCG-vaccinated/rHBHA-boosted
mice promotes protection speciﬁcally at the long term, an
issue that deserves future investigation. Interestingly, it has
been reported recently that in early M. tuberculosis infection
regulatory T cells could be delaying the onset of eﬀector T
cells in the lung [32].
A very moderate increase in BCG-induced spleen IFN-
γ production (independent of the route of infection, i.n.
versus aerosol) of infected mice by the s.c. rHBHA boosting
was found in comparison with those reported from BCG-
vaccinated nHBHA/boosted [23]. In the previous report,
we proposed that the nHBHA boosting eﬀect of BCG-
inducedprotectiveimmunity couldbethrough a mechanism
independentofIFN-γ [23]. In thisstudy,we donot knowthe
impact of the moderate systemic IFN-γ production on the
control of M. tuberculosis infection. However, from the data
it is also possible that, although the reduction of bacterial
load in the spleen is signiﬁcant (P<0.05) upon aerosol
infection (Table 1), the methylated pattern in the C-terminal
domain ofHBHAis required to promote the developmentof
a more sustained cellular response in the lung compartment,
as it was observed for the i.n. infected mice. However, more
e x p e r i m e n t sa r en e c e s s a r yt oa d d r e s st h i si s s u e .
Thus, in agreement with our previous ﬁndings, an
environment of IL-12 and TGF-β production in long-
term prime-boost regimens could promote enhanced BCG-
induced protective immunity to contain M. tuberculosis
locally and at peripheral locations, suggesting that eﬀector
and memory T cells could be involved [25, 26, 33–35]. InClinical and Developmental Immunology 7
agreement with this, it has been reported that protection
against M. tuberculosis induced by the prime-boost either
parenterally, i.n., or through other routes did not necessarily
correlate with the presence of IFN-γ-producing circulating T
cells [36, 37].
Insummary, severalpointsarise fromthisstudy:ﬁrst, the
data are consistent with the fact that heterologous prime-
boost protocols are a very eﬀective way to enhance BCG-
induced protective immunity and, second, the dispensability
of the methylation pattern in the C-terminal domain of
HBHA to enhance this protection after i.n. but not after
aerosol M. tuberculosis infection. It is the IL-12 production
and not IFN-γ that is very important not only to promote
Th1 cellular immune responses but also for the development
and maintenance of long-term memory T cells of infected
mice. In addition, this report provides evidence that rHBHA
may be used to improve current BCGvaccination schemes in
heterologousprime/boost regimens, particularly relevant for
reducing the incidence of disseminated tuberculosis.
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